Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Biol Psychiatry. 2014 Apr 25;77(5):475–487. doi: 10.1016/j.biopsych.2014.04.009

Figure 4. Chronic systemic administration of AM1710 reversed paclitaxel-induced neuropathic pain with similar efficacy in CB1KO and WT mice.

Figure 4

(A, B) AM1710 (5 mg/kg/day i.p. × 8 days) reversed paclitaxel-induced (A) mechanical and (B) cold allodynia in both CB1KO and WT littermates. (C, D) AM1710 (5 mg/kg/day i.p. × 8 days) did not alter (C) mechanical or (D) cold responsiveness in cremophor-treated CB1KO or WT mice. BL, pre-paclitaxel baseline; PTX, post-paclitaxel baseline; CR, post-cremophor baseline. Data are expressed as mean ± SEM (n=4–8 per group). *P<0.05 vs. vehicle, one-way ANOVA followed by Bonferroni post hoc test. #P<0.05 vs. pre-paclitaxel baseline, repeated measures ANOVA.